Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.43 |
| ▸ | TERT | O14746 | 2/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 2/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.35 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171015 | 0.91 | KDR (0.52) | KDRCSF1RPLK1 | |
| SCHEMBL18170425 | 0.90 | KDR (0.51) | KDRNAMPTCSF1RPLK1 | |
| SCHEMBL18170763 | 0.90 | KDR (0.57) | KDRTOP2BTERTNAMPTPLK1 | |
| SCHEMBL18170849 | 0.89 | KDR (0.54) | KDRCSF1R | |
| SCHEMBL18170850 | 0.88 | KDR (0.46) | KDRTOP2BTERT | |
| SCHEMBL18170694 | 0.85 | TOP2B (0.44) | KDRTOP2BTERTNAMPT | |
| SCHEMBL18170458 | 0.85 | KDR (0.47) | KDRTOP2BTERTNAMPTPLK1 | |
| SCHEMBL18170471 | 0.85 | KDR (0.46) | KDRTOP2BTERTSMN1; SMN2NAMPT | |
| SCHEMBL18170486 | 0.84 | KDR (0.59) | KDRTOP2B | |
| SCHEMBL18170429 | 0.84 | KDR (0.47) | KDRTOP2BSMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | claimed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | claimed |
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNK1, NFKBIA | KDR 1662/4885TOP2B 866/4885TERT 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.